Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Total Non-Current Liabilities (2016 - 2025)

Nutex Health's Total Non-Current Liabilities history spans 10 years, with the latest figure at $11.5 million for Q1 2025.

  • For Q1 2025, Total Non-Current Liabilities changed N/A year-over-year to $11.5 million; the TTM value through Mar 2025 reached $11.5 million, changed N/A, while the annual FY2024 figure was $11.8 million, 9.19% down from the prior year.
  • Total Non-Current Liabilities for Q1 2025 was $11.5 million at Nutex Health, down from $11.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $13.8 million in Q1 2023 and bottomed at $30680.0 in Q4 2022.
  • The 4-year median for Total Non-Current Liabilities is $12.1 million (2024), against an average of $10.5 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 42139.8% in 2023 before it dropped 9.39% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $30680.0 in 2022, then surged by 42139.8% to $13.0 million in 2023, then decreased by 9.19% to $11.8 million in 2024, then fell by 2.62% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Total Non-Current Liabilities are $11.5 million (Q1 2025), $11.8 million (Q4 2024), and $12.1 million (Q3 2024).